Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Drug

HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors

Fineline Cube Dec 7, 2024

Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...

Company Drug

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment

Fineline Cube Dec 6, 2024

The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang...

Company Deals

Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine

Fineline Cube Dec 6, 2024

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution...

Company Deals

GSK plc Partners with Muna Therapeutics to Discover Alzheimer’s Disease Treatment Targets

Fineline Cube Dec 6, 2024

GSK plc (NYSE: GSK) has announced a new partnership with Danish biotech firm Muna Therapeutics,...

Company Drug

Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma

Fineline Cube Dec 6, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received breakthrough therapy...

Company Drug

Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment

Fineline Cube Dec 6, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the US Food and Drug Administration...

Company Drug

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI

Fineline Cube Dec 6, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...

Company Deals

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion

Fineline Cube Dec 6, 2024

China-based ophthalmic medical device manufacturer, Eyebright Medical Technology Co., Ltd (SHA: 688050), has announced plans...

Company Deals

Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators

Fineline Cube Dec 6, 2024

US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly...

Company Deals Drug

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment

Fineline Cube Dec 6, 2024

US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma...

Company Drug

AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer

Fineline Cube Dec 6, 2024

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from...

Company

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment

Fineline Cube Dec 6, 2024

US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the expansion of its...

Company

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility

Fineline Cube Dec 6, 2024

US biotech company Amgen (NASDAQ: AMGN) has announced plans to construct a second drug substance...

Company Drug

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral

Fineline Cube Dec 6, 2024

US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...

Company Drug

CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia

Fineline Cube Dec 6, 2024

China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...

Company

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction

Fineline Cube Dec 5, 2024

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the...

Company Deals

Novavax to Sell Czech Manufacturing Facility to Novo Nordisk for $200 Million

Fineline Cube Dec 5, 2024

US-based Novavax, Inc. (NASDAQ: NVAX) has reached an agreement to sell its manufacturing facility located...

Hospital Policy / Regulatory

China’s Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care

Fineline Cube Dec 5, 2024

The National Health Commission, in conjunction with three other bureaus, has issued the “Notice on...

Company Drug

Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study

Fineline Cube Dec 5, 2024

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from...

Company Drug

Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer

Fineline Cube Dec 5, 2024

Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track...

Posts pagination

1 … 295 296 297 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.